Biontech Se's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Biontech Se in the fourth quarter 2025?
Biontech Se had a negative return on equity (ROE) of -5.84%, due to the net loss of $-1 billion, during the twelve months ending in the fourth quarter 2025.

Within the Biotechnology & Pharmaceuticals industry 22 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 2622.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	12.29 %	-0.96 %	-0.96 %	-0.96 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-1,272	-745	-745	-745	-745
Return On Equity (TTM)	-5.84 %	-3.52 %	-3.51 %	-3.5 %	-3.49 %
BNTX's Total Ranking	# 2622	# 0	#	#	#
Equity (TTM) in Millions	22,562	21,531	21,531	21,531	20,092
Seq. Equity Change	4.79 %	0 %	0 %	7.16 %	-7.58 %
Seq. Net Income Change	-	-	-	-	-

Back to BNTX Management Effectiveness >> BNTX's 5 Years Annual ROE >> Compare BNTX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 23
Sector	# 223
Overall	# 2622

Return On Equity Statistics
High	Average	Low
86.54 %	13.38 %	-36.31 %
(Dec 31 2021)		(Dec 31 2019)

News about Biontech Se Return on Equity ROE

BioNTechs Leadership Transition and Promising Oncology Pipeline Underscore Its Strategic Evolution

In a significant development for the biopharmaceutical landscape, BioNTech SE (Nasdaq: BNTX) has announced that Ryan Richardson, the company’s Chief Strategy Officer, will vacate his position on the Management Board effective September 30, 2025. This decision was made by mutual agreement to allow Richardson to pursue new professional opportunities. His departure, while marking a pivotal moment in the company s executive leadership, comes at a time when BioNTech is poised to showcase its advancements in oncology during the forthcoming American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 30 to June 3, 2025.The transition in BioNTech’s leadership is indicative of the dynamic nature of the biopharmaceutical industry, where strategic shifts are often essential for staying competitive and innovative. The company has commenced the process of reallocating Richardson s responsibilities among other members of the Management Board, underscoring its commitment to ensuring a seamless transition. The management team at BioNTech is expected to bring forth fresh perspectives and sustained momentum in delivering groundbreaking therapies, especially as the organization navigates this change.

BNTX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	22,562	20,092	22,396	21,455	13,461
Y / Y Equity Change	12.29 %	-10.29 %	4.38 %	59.39 %	702.33 %
Net Income in Millions	-1,284	-720	1,006	9,938	12,176
Y / Y Net Income Change	-	-	-89.88 %	-18.38 %	70115.83 %
Return On Equity	-5.69 %	-3.58 %	4.49 %	46.32 %	90.46 %

Back to BNTX Management Effectiveness >> BNTX's 5 Years Annual ROE >> Compare BNTX ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BNTX's' Return on Equity at Yahoo Finance
BNTX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BNTX's Competitors
Subscribers only: Roe for Biontech Se's Suppliers
Subscribers only: Return On Equity for BNTX's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector

ROE

Date modified: 2026-07-07T09:38:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.